DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer.

Hetakshi KuraniSeyedeh Fatemeh Razavipour Kuzhuvelil B Harikumar Matthew R Dunworth Andrew J EwaldApsra NasirGray PearsonDerek Van BoovenZhiqun Zhou Diana J Azzam Claes Wahlestedt Joyce M Slingerland

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

DOT1L emerges as a key CSC regulator in TNBC. Present data support further clinical investigation of DOT1L inhibitors to target stem cell-enriched TNBC.

Keyphrases

cancer stem cells
stem cells
energy transfer
electronic health record
cell therapy